X0306 4 2020-11-02 0 0001800315 Galecto, Inc. GLTO 0001609405 Khuong Chau Quang C/O GALECTO, INC. OLE MAALOES VEJ 3 COPENHAGEN N G7 DK-2200 DENMARK 1 0 1 0 Common Shares 2020-11-02 4 C 0 2055824 A 2055824 I See footnote Common Shares 2020-11-02 4 C 0 822311 A 822311 I See footnote Common Shares 2020-11-02 4 C 0 191787 A 191787 I See footnote Common Shares 2020-11-02 4 P 0 523833 15.00 A 2579657 I See footnote Common Shares 2020-11-02 4 P 0 209500 15.00 A 1031811 I See footnote Series D Preferred Stock 2020-09-25 4 A 0 148395 27.11 D Common Shares 385782 148395 I See footnote Series D Preferred Stock 2020-09-25 4 A 0 59350 27.11 D Common Shares 154292 59350 I See footnote Series D Preferred Stock 2020-09-25 4 A 0 73773 27.11 D Common Shares 191787 73773 I See footnote Series C-2 Preferred Stock 2020-11-02 4 C 0 291999 D Common Shares 759110 0 I See footnote Series C-2 Preferred Stock 2020-11-02 4 C 0 116800 D Common Shares 303645 0 I See footnote Series C-4 Preferred Stock 2020-11-02 4 C 0 272533 D Common Shares 708504 0 I See footnote Series C-4 Preferred Stock 2020-11-02 4 C 0 109013 D Common Shares 283402 0 I See footnote Series C-5 Preferred Stock 2020-11-02 4 C 0 77866 D Common Shares 202428 0 I See footnote Series C-5 Preferred Stock 2020-11-02 4 C 0 31147 D Common Shares 80972 0 I See footnote Series D Preferred Stock 2020-11-02 4 C 0 148395 D Common Shares 385782 0 I See footnote Series D Preferred Stock 2020-11-02 4 C 0 59350 D Common Shares 154292 0 I See footnote Series D Preferred Stock 2020-11-02 4 C 0 73773 D Common Shares 191787 0 I See footnote The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date. These securities are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VII and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is an employee of OrbiMed Advisors. OrbiMed Advisors exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by OPI VII. These securities are held of record by OrbiMed Israel Partners II, L.P. ("OIP II"). OrbiMed Israel is the general partner of OIP II, and OrbiMed Limited is the managing member of OrbiMed Israel. By virtue of such relationships, OrbiMed Israel and OrbiMed Limited may be deemed to have voting and investment power over the securities held by OIP II and as a result may be deemed to have beneficial ownership over such securities. OrbiMed Limited exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan Silverstein, Nissim Darvish, Anat Naschitz, and Erez Chimovits, each of whom disclaims beneficial ownership of the securities held by OIP II. These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis Master Fund"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis Master Fund and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by Genesis Master Fund and as a result may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by Genesis Master Fund. This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. /s/ Jonathan Freve, attorney-in-fact 2020-11-04